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Purpose:	  	  The	  primary	  objective	  of	  this	  study	  was	  to	  examine	  graft	  loss	  rate	  following	  institution	  
specific	   immunosuppression	   (IS)	   modulation	   in	   the	   treatment	   of	   BK	   virus	   re-­‐activation	   post-­‐
renal	  transplant.	  	  
	  
Methods:	  A	  retrospective	  chart	  analysis	  identified	  212	  patients	  over	  18	  years	  of	  age	  receiving	  a	  
single	   renal	   allograft	   at	   UNC	   Hospitals	   between	   2005	   and	   2013	  with	   reactivated	   BK	   virus	   as	  
confirmed	   by	   the	   presence	   of	   decoy	   cells	   on	   urine	   cytology	   through	   follow-­‐up	   until	   August	  
2014.	  
	  	  
Results:	  Of	  the	  212	  renal	  allografts	  with	  reactivated	  BK,	  33	  (15.6%)	  had	  progressed	  to	  BKVAN	  
(BK	  virus-­‐associated	  nephropathy).	  Renal	  biopsy	  identified	  15	  patients	  with	  Stage	  A	  BKVAN,	  16	  
with	  Stage	  B	  and	  2	  with	  Stage	  C.	   IS	   regimen	  changes	   included	  reduction	   in	   tacrolimus	   trough	  
goals	   (60.6%),	   reduction	   in	  mycophenolic	   acid	   (24.2%),	   discontinuation	   of	  mycophenolic	   acid	  
(81.8%),	   the	   addition	   of	   leflunomide	   (57.5%)	   or	   azathioprine	   (18%)	   and	   re-­‐initiation	   of	  
corticosteroids	   (65%).	   IS	   changes	   preserved	   graft	   function	   in	   97%	   of	   patients,	   with	   only	   one	  
graft	  lost	  (3%)	  following	  confirmed	  diagnosis	  with	  BKVAN.	  
	  
Conclusion:	  UNC	  Hospitals	   reports	  a	  graft	   loss	   rate	  of	  only	  3%	  among	  all	  diagnosed	   stages	  of	  
BKVN.	  In	  contrast	  to	  current	  guidelines,	  UNC	  follows	  a	  protocol	  with	  more	  aggressive	  screening,	  
a	   lower	   threshold	   for	   acquiring	   blood	   PCRs	   and	   IS	   adjustment,	   along	   with	   the	   addition	   of	  
leflunomide	  and	  prednisone	  therapy.	  	  
	  
INTRODUCTION	  
BK	  Virus	  Background	  	  
BK	   virus	   is	   a	   member	   of	   the	   polyoma	   virus	   family	   that	   resides	   as	   a	   latent	   infection,	  
remaining	  dormant	  within	  the	  kidneys	  in	  80-­‐90%	  of	  the	  general	  population1,	  2.	  Despite	  the	  large	  
percentage	   of	   the	   population	   carrying	   this	   virus,	   BK	   virus	   manifests	   as	   clinical	   disease	   in	  
immunocompromised	   patients.	   Bone	   marrow	   transplant	   recipients	   suffer	   from	   hemorrhagic	  
cystitis	  while	  renal	  transplant	  patients	  risk	  graft	  loss	  through	  BK	  virus	  nephropathy	  (BKVAN)1,	  2,	  
3.	  BK	  virus	   is	  an	  opportunistic	   infection	   that,	  once	   reactivated,	   is	  a	  progressive,	   lytic	   infection	  
that	  is	  spread	  through	  cell-­‐to-­‐cell	  contact1,	  2.	  
Cases	  of	  diagnosed	  BKVAN	   following	  other	   solid	  organ	   transplants	  have	   thus	   far	  been	  
limited.	   Joseph,	   A,	   et	   al.	   have	   recently	   reported	   the	   diagnosis	   of	   BKVAN	   in	   2	   patient	   cases	  
following	   heart	   transplantation	   where	   both	   patients	   were	   receiving	   tacrolimus,	   MMF	   and	  
prednisone	   as	   immunosuppressive	   therapy	   after	   surgery.	   Decreased	   renal	   function	   has	   been	  
seen	   in	   cardiac	   transplant	   patients,	   defined	   as	   an	   eGFR<30	  mL/min/1.73m2,	   in	   10.9%	   of	   the	  
transplanted	   population.	   Despite	   a	   reported	   7%	   incidence	   of	   BK	   viruria	   this	   decline	   in	   renal	  
function	  was	  attributed	   to	  other	  causes,	   including	  diabetes,	  hypertension,	   chronic	  calcineurin	  
inhibitor	  toxicity	  or	  other	  hemodynamic	  changes	  as	  renal	  biopsies	  were	  often	  not	  performed4.	  	  	  
Ducharme-­‐Smith,	   A,	   et	   al.	   performed	   a	   retrospective	   study	   of	   pediatric	   heart	   transplant	  
patients	  from	  May	  1989	  to	  July	  2013	  to	   identify	  those	  with	  CKD	  ≥	  stage	  2.	  Of	  the	  83	  patients	  
screened,	   34%	  had	  BK	   viruria,	   8%	  had	  BK	   viremia	   and	  1	   patient	  with	  biopsy-­‐proven	  BKVAN5.	  
These	  recent	  reports	  provide	  evidence	  that	  other	  solid	  organ	  transplants	  could	  be	  at	  risk	  of	  BK	  
viral	  reactivation,	  aside	  from	  renal	  transplants.	  
	  
BK	  Virus	  Risk	  Factors	  
	   Since	   BK	   virus	   resides	   within	   the	   urogenital	   tract,	   renal	   transplant	   patients	   are	  more	  
susceptible	   to	   reactivation	   of	   this	   infection.	   Reactivation	   can	   be	   due	   to	   direct	   and	   indirect	  
causes.	  Direct	   causes	   include	  damage	   to	   the	  organ	  prior	   to	   transplant,	   cold	   ischemic	   time	  or	  
improper/rough	  handling	  of	   the	  kidney1.	  All	  of	   these	   factors	  can	  weaken	  the	  kidney	  and	  thus	  
cause	   it	   to	   be	  more	   susceptible	   to	   infection	   post-­‐transplant.	   Indirect	   causes	   associated	  with	  
reactivation	   are	   the	   potent	   immunosuppression	   regimens	   that	   are	   required	   of	   patients	   after	  
transplantation.	   The	   emergence	   of	   more	   potent	   agents,	   including	   tacrolimus,	   mycophenolic	  
acid	   and	   cyclosporine	   has	   been	   accompanied	   with	   an	   increased	   incidence	   of	   BK	   viral	  
reactivation	  in	  the	  renal	  transplant	  patient	  population1,	  6.	  	  
	   Additional	  patient	  demographics	  can	  place	  certain	  patient	  populations	  at	  an	   increased	  
risk	   of	   BK	   viral	   reactivation	   post-­‐transplant.	   These	   include	   the	   seropositive	   status	   of	  
donors/recipients,	   deceased	   donors,	   male	   gender,	   older	   age,	   Caucasian	   race,	   concurrent	  
diagnosis	  with	  diabetes	  mellitus	  and	  any	  episodes	  of	  acute	  rejection7.	  Any	  concurrent	  disease	  
states	  or	  patient	  characteristics	  that	  result	  in	  weakened	  kidneys	  pose	  additional	  risks2.	  
	  
BK	  Virus	  Pathophysiology,	  Detection	  and	  Diagnosis	  
It	   is	   recommended	   that	   screening	   kidney	   transplant	   recipients	   for	  BK	   virus	   replication	  
via	  decoy	  cells	  on	  urine	  cytology	  should	  be	  done	  every	  other	  week	  for	  the	  first	  three	  months,	  
then	  monthly	  until	  month	  6,	  then	  every	  3	  months	  until	  2	  years	  post-­‐transplant.	  If	  urine	  cytology	  
is	  positive,	  a	  monthly	  BK	  PCR	  (plasma	  screening)	  is	  done	  for	  the	  first	  6	  months	  and	  then	  every	  3	  
months	   until	   2	   years	   post-­‐transplant1.	   If	   plasma	   levels	   remain	   constant,	   or	   increase,	   a	   renal	  
biopsy	  is	  required	  for	  definitive	  BKVAN	  diagnosis.	  	  
	   BK	  viral	  reactivation	  typically	  lacks	  viral	  infection	  symptoms	  and	  will	  initially	  manifest	  as	  
renal	   dysfunction,	   seen	   as	   an	   elevation	   in	   a	   patient’s	   serum	   creatinine.	   This	   increase	   ranges	  
from	  minimal	  to	  significant	  depending	  on	  severity	  of	  infection.	  The	  initial	  detection	  of	  BK	  virus	  
reactivation	  is	  indicated	  by	  the	  presence	  of	  decoy	  cells	  on	  urine	  cytology,	  known	  as	  BK	  viruria.	  
Decoy	  cells	  are	  characterized	  by	  an	  abnormally	  large	  nucleus,	  indicative	  of	  a	  viral	  inclusion	  and	  
actively	   replicating	  BK	  virus2.	  Progression	  of	   infection	  moves	   from	   the	  urine	   to	   the	  blood,	  BK	  
viremia,	   and	   can	  be	   confirmed	  by	  a	  blood	  PCR	  with	  positive	  detection	  of	  BK	  virus	   copies.	  BK	  
viremia	  is	  seen	  in	  approximately	  13%	  of	  renal	  transplant	  patients8,	  9.	  Further	  progression	  of	  the	  
infection	  occurs	  with	  infection	  of	  the	  graft	  itself,	  as	  BKVAN.	  A	  definitive	  diagnosis	  of	  BKVAN	  can	  
only	  be	  completed	  via	  renal	  biopsy.	  Approximately	  8%	  of	  renal	  transplant	  patients	  will	  progress	  
to	  BKVAN,	  resulting	  in	  graft	  loss	  in	  10	  to	  >90%	  of	  patients11.	  The	  BK	  virus	  can	  progress	  from	  the	  
urine,	   to	   the	   blood	   and	   ultimately	   to	   the	   kidney,	  with	   no	   other	   clinical	  manifestations	   other	  
than	  impaired	  renal	  function	  and	  an	  elevated	  SCr.	  1-­‐3,6.	  	  
	  
Stages	  and	  Prognosis	  of	  BKVAN	  	  
	   The	   renal	   biopsy	   used	   to	   confirm	   diagnosis	   of	   BKVAN	   is	   also	   used	   to	   stage	   the	  
progression	  of	  BK	  virus	  and	  how	  far	  the	  infection	  of	  the	  kidney	  has	  progressed2.	  The	  3	  stages,	  
their	  characteristics	  and	  prognosis	  at	  each	  stage	  at	  listed	  in	  Table	  1.	  	  
Table	  1:	  Staging	  Criteria	  for	  Biopsy	  Confirmed	  BKVAN1,2	  
Stage	  	   Characteristicsa	   Prognosis	   Graft	  Loss	  
A	   • Minimal	  inflammation	  
• Less	  than	  10%	  tubular	  atrophy	  
and	  interstitial	  fibrosis	  
• Diagnosed	  early	  
• Responds	   favorable	   to	  
therapy	  
<	  10%	  
B	   • Less	  than	  50%	  tubular	  atrophy	  
and	  interstitial	  fibrosis	  
• Can	   be	   reversed	   to	  
Stage	   A	   with	  
treatment	  
50	  –	  75%	  	  
C	   • More	   than	   50%	   tubular	  
atrophy	  and	  interstitial	  fibrosis	  
• Irreparable	  damage	  
Treatment	   often	  
ineffective	  
>	  80%	  
a	  Percentage	  of	  tubular	  atrophy	  and	  interstitial	  fibrosis	  is	  based	  on	  the	  biopsy	  sample	  that	  is	  taken	  during	  diagnosis.	  
 
	   Currently,	  there	  is	  no	  widely	  accepted	  protocol	  to	  follow	  for	  patients	  presenting	  with	  BK	  
virus	   reactivation.	   This	   study	   aims	   to	   evaluate	   the	   use	   of	   a	   more	   intense	   post-­‐transplant	  
monitoring	  and	   lower	  threshold	  for	   immunosuppression	  regimen	  changes	  which	  are	  currently	  
used	  at	  UNC	  Hospitals.	  	  
	   The	   mainstays	   of	   therapy	   in	   BKVAN	   treatment	   rely	   heavily	   on	   reduction	   in	  
immunosuppression	   agents.	   It	   is	   generally	   accepted	   to	   reduce	   one	   agent	   at	   a	   time	   until	   a	  
delayed	  progression	  of	  BK	  virus	   replication	   is	   seen.	   Should	  a	   reduction	  not	   suffice,	   additional	  
agents	  have	  been	  tested	  as	  adjuncts	  to	  therapy,	  including,	  but	  not	  limited	  to	  leflunomide,	  IVIG,	  
fluoroquinolones,	  brincidofovir	  and	  cidofovir1,8.	  However,	  there	  is	  no	  conclusive	  evidence	  as	  to	  




	   The	  study	  was	  conducted	  as	  a	  retrospective	  chart	  analysis	  to	  assess	  outcomes	  in	  renal	  
transplant	   patients;	   specific	   to	   the	   infection	   of	   BK	   virus,	   viral	   progression,	   treatment	   and	  
potential	   graft	   loss.	   Patients	   were	   included	   that	   had	   received	   a	   renal	   transplant	   at	   UNC	  
Hospitals	  during	  2005	  and	  2013	  and	   tested	  positive	   for	  BK	  virus	  at	  any	  point	  after	   transplant	  
during	  their	  follow-­‐up	  through	  August	  2014.	  	  
	  
Primary	  Objective	  
The	  primary	  objective	  of	   this	  study	  was	  to	  examine	  the	  graft	   loss	   rate	  due	  to	  BK	  virus	  
following	  the	  UNC-­‐specific	  IS	  modulation	  post-­‐renal	  transplant,	  as	  seen	  in	  Figure	  1.	  In	  assessing	  
the	   effectiveness	   of	   the	   institution-­‐specific	   protocol,	   the	   information	   gathered	   would	  
potentially	   assist	   in	   the	   development	   of	   a	   standardized	   protocol	   in	   the	   prevention	   and	  











	   A	   list	   of	   all	   patients	   receiving	   a	   renal	   transplant	   at	   UNC	  Hospitals	   between	   2005	   and	  
2013	  was	  compiled.	  This	  list	  was	  further	  limited	  to	  only	  include	  transplant	  recipients	  that	  tested	  
positive	  for	  BK	  virus	  based	  on	  urine	  cytology,	  at	  any	  time	  post-­‐transplantation	  during	  follow-­‐up.	  
	  
Inclusion	  Criteria	  
	   All	  adult	  patients	   receiving	  a	   renal	   transplant	  at	  UNC	  Hospitals	  between	   January	  2005	  
and	  December	  2013	  were	  considered	  for	  inclusion,	  with	  documented	  follow-­‐up	  through	  August	  
2014.	   	  The	   included	  date	  range	  was	  chosen	  based	  on	  the	  time	  when	  the	  EMR	  TransChart,	  an	  
EMR	   with	   specific	   functionality	   for	   transplant	   patients	   and	   better	   documentation,	   was	  
introduced	  at	  UNC	  Hospitals.	  Additionally,	  it	  was	  the	  use	  of	  TransChart	  that	  prompted	  a	  more	  
consistent	  following	  of	  the	  UNC	  BK	  Virus	  Protocol	  that	  required	  more	  significant	  monitoring.	  As	  
it	  was	  observed	  that	  the	  protocol	  was	  followed	  more	  closely,	   these	  dates	  allow	  us	  to	  analyze	  




	   Patients	  were	  excluded	  if	  they	  were	  less	  than	  18	  years	  old,	  received	  a	  combined	  organ	  
transplant	  (liver/kidney,	  liver/pancreas,	  heart/kidney,	  etc.).	  Combined	  transplant	  patients	  were	  
excluded	   due	   to	   differing	   immunosuppression	   regimens	   employed	   to	   prevent	   multiple	   graft	  
rejection.	  This	  exclusion	  was	  chosen	  to	  prevent	  skewing	  the	  data	  for	  the	  incidence	  of	  BKVAN	  in	  
renal	  transplant	  patients	  specifically.	  
	  
Data	  Collection	  
	   Data	   collection	   was	   performed	   using	   multiple	   EMRs	   that	   had	   been	   used	   at	   UNC	  
Hospitals	  by	  the	  transplant	  treatment	  team	  during	  the	  study	  inclusion	  period,	  including	  WebCis,	  
TransChart	   and	   EPIC.	   Patient	   demographics	   that	   were	   gathered	   included	   age	   at	   time	   of	  
transplant,	  ethnicity,	  gender,	  reason	  for	  transplant,	  donor	  type	  (alive	  vs.	  deceased),	   induction	  
antibodies,	  time	  to	  first	  decoy	  cell	  (+)	  on	  urine	  cytology,	  time	  to	  first	  blood	  BK	  PCR	  (+),	  time	  to	  
first	  BKVAN	  (+)	  and	  stage	  of	  BKVAN	  as	  confirmed	  by	  renal	  biopsy,	  medications	  and	  drug	  levels	  in	  
the	  month	  prior	  to	  BKVAN	  (including	  tacrolimus,	  cyclosporine,	  mycophenolic	  acid	  and	  steroids),	  
and	   rejection	   data	   on	   BKVAN	   patients	   including	   type	   of	   rejection	   (acute	   and	   chronic),	   time	  
before/after	  BKVAN	  	  diagnosis	  as	  well	  as	  medications	  for	  treatment. 
	  
Statistical	  Analysis	  	  
	   All	   statistical	   analysis	   was	   completed	   by	   the	   transplant	   department	   at	   UNC	   Hospitals	  
using	  GraphPad™	  software.	  The	  patient	  population	  was	  subdivided	  into	  two	  groups,	  no-­‐BKVAN	  
and	  BKVAN.	  Results	  were	  considered	  significant	  with	  a	  T-­‐test	  value	  of	  p	  ≤	  0.05.	  
	  
RESULTS	  
Table	  2:	  Patient	  Demographicsa	  

















































a	   In	   each	   group,	   there	   were	   some	   transplant	   patient’s	   charts	   that	   did	   not	   have	   the	   specific	   donor	   information	  
reported.	  As	  such,	  calculations	  of	  patient	  demographics	  were	  completed	  using	  the	  information	  that	  was	  reported.	  
In	  the	  No	  BKVAN	  group,	  donor	  age	  was	  only	  reported	  for	  147	  donors,	  gender	  for	  141	  donors	  and	  T-­‐cell	  depleting	  
induction	  for	  94	  donors.	  In	  the	  BKVAN	  cohort,	  donor	  age	  was	  only	  reported	  for	  28	  donors,	  gender	  for	  28	  donors	  
and	  induction	  information	  for	  27	  donors.	  
	  
Primary	  Outcome	  
	   A	  total	  of	  542	  patients	  received	  a	  single	  renal	  transplant	  at	  UNC	  Hospitals	  between	  2005	  
and	  2013.	  Of	  these,	  	  212	  renal	  allografts	  had	  reactivated	  BK	  and	  33	  (15.6%)	  had	  progressed	  to	  
BKVN.	  Renal	  biopsy	  identified	  15	  patients	  with	  Stage	  A	  BKVAN,	  16	  with	  Stage	  B	  and	  2	  with	  Stage	  
C.	  The	  immunosuppression	  changes	  made,	  as	  seen	  in	  Table	  3,	  preserved	  graft	  function	  in	  97%	  
of	  patients,	  with	  only	  one	  graft	  lost	  (1/33,	  3%)	  following	  confirmed	  diagnosis	  with	  BKVAN.	  The	  
one	  graft	  that	  was	  lost	  had	  flourid	  disease,	  stage	  C	  BKVAN.	  	  
	  
Figure	  2:	  Primary	  Outcome	  Flowchart	  
	  
Table	  3:	  Immunosuppression	  Modifications	  due	  to	  BKVANa	  
AZA	  used	  in	  place	  of	  MPA	   18%	  (n=6/33)	  
MPA	  dose	  reduced	   24.2%	  (n=8/33)	  
MPA	  dose	  reduced,	  then	  held	  or	  discontinued	   81.8%	  (n=27/33)	  
Tacrolimus	  dose	  reduced	   60.6%	  (n=20/33)	  
Leflunomide	  initiated	   57.5%	  (n=19/33)	  
Reinitiation	  of	  corticosteroids	   63.6%	  (n=21/33)	  
a	  The	  changes	  in	  immunosuppression	  could	  have	  been	  used	  as	  the	  only	  change	  made	  in	  a	  patient’s	  regimen,	  or	  in	  
combination	  with	  other	  changes	  listed	  in	  the	  table	  above.	  	  
Immunosuppressives	  Doses	  at	  1,	  3,	  6,	  and	  12-­‐months	  post-­‐transplant	  
	  

























p-­‐value	   <0.01	   Not	  significant	   Not	  significant	   Not	  significant	  
	  
Table	  5:	  Average	  mycophenolic	  acid	  doses	  1,	  3,	  6	  and	  12-­‐months	  post-­‐transplant	  
	  
Mycophenolic	  Aid	  (MPA,	  mg/day)	  
Month	  post-­‐





















p-­‐value	   <0.01	   <0.02	   Not	  significant	   Not	  significant	  
	  
































	   The	  emergence	  of	  BK	  virus	  infection	  in	  renal	  transplant	  patients	  poses	  a	  serious	  risk	  to	  
graft	  survival	  in	  this	  population.	  Since	  the	  virus	  progresses	  without	  the	  typical	  symptoms	  of	  viral	  
disease,	  including	  fever,	  malaise,	  myalgias,	  leukopenia,	  anemia,	  it	  can	  often	  go	  unnoticed	  until	  
it	  has	  infected	  the	  graft	  itself2.	  The	  published	  rates	  of	  graft	  loss	  for	  stages	  A,	  B	  and	  C	  BKVAN	  are	  
<10%,	  ~50%	  and	  <80%,	   respectively1,10.	  The	  key	   to	  preserve	   the	  graft	  and	  graft	   function	   is	   to	  
prevent	  infection	  or	  to	  prevent	  the	  progression	  of	  infection.	  	  	  
Weiss,	  AS	  et	  al.	  compared	  two	  strategies	  for	  BKVAN	  management,	  immunosuppression	  
withdrawal	   vs.	   immunosuppression	   reduction.	  The	   results	   found	   that	   the	  early	  elimination	  of	  
one	   immunosuppressant	   is	   significantly	   more	   effective	   in	   preserving	   graft	   function	   in	   renal	  
transplant	   patients	   with	   a	   1-­‐year	   graft	   survival	   rate	   of	   87.8%	   with	   immunosuppression	  
withdrawal	  vs.	  56.2%	  with	  immunosuppression	  reduction	  (p-­‐value	  0.03)11.	  	  
	   The	   American	   Society	   of	   Transplantation	   infectious	   diseases	   community	   of	   practice	  
supports	   treatment	   via	   immunosuppression	   reduction	   of	   BK	   virus	   infection	   after	   a	   positive	  
blood	  BK	  PCR	  test	  and	  suggest	  2	  potential	   strategies	  by	  reducing	  the	  calcineurin	   inhibitor	  25-­‐
50%,	   followed	   by	   reduction	   of	   the	   anti-­‐proliferative	   by	   50%	   and	   then	   discontinuation	   of	   the	  
anti-­‐proliferative,	   or	   by	   first	   reducing	   the	   anti-­‐proliferative	   by	   50%,	   then	   reduce	   calcineurin	  
inhibitor	  25-­‐50%	  and	  then	  discontinue	  the	  anti-­‐proliferative.	  However,	  there	  was	  no	  reported	  
efficacy	   on	   using	   either	   of	   these	   strategies	   on	   graft	   function	   or	   loss1.	   Additional	   strategies,	  
including	   the	   addition	   of	   fluoroquinolones	   as	   a	   means	   of	   preventing	   BK	   viruria	   have	   been	  
considered	  post-­‐renal	  transplant.	  Knoll,	  GA,	  et	  al.	  sought	  to	  determine	  if	  levofloxacin	  could	  be	  
used	  to	  prevent	  BK	  viruria	  and	  found	  a	  29%	   incidence	  of	  BK	  viruria	   in	  the	  group	  treated	  with	  
levofloxacin	  vs.	  33.3%	  in	  the	  placebo	  group	  (p=0.58)12.	  Additionally,	  there	  was	  an	  increased	  risk	  
of	  infection	  resistant	  to	  fluoroquinolones	  seen	  in	  the	  group	  treated	  with	  levofloxacin	  (58.3%	  vs.	  
33.3%	  in	  the	  placebo	  group,	  risk	  ratio	  1.75)12.	  
Schaub,	  S,	  et	  al.	  assessed	  the	  mean	  time	  to	  viremia	  clearance	  after	  reduction	  of	  target	  
tacrolimus	   trough	   levels,	   followed	  by	   a	   reduction	  of	  MMF	  dose.	   These	   changes	   resulted	   in	   a	  
mean	  clearance	  of	  BK	  virus	  plasma	   levels	  within	  4	  months	  of	   initiation.	  These	  results	  support	  
the	  strategy	  of	  using	  immunosuppression	  reduction.	  However,	  there	  was	  limited	  follow-­‐up	  and	  
the	  endpoints	  of	  the	  study	  did	  not	  look	  at	  rates	  of	  BK	  nephropathy	  or	  graft	  loss	  after	  changes	  
were	  made	  in	  immunosuppressive	  therapy13.	  	  
	   The	   protocol	   used	   by	   UNC	   Hospitals	   (see	   Figure	   1)	   follows	   a	   similar	   methodology	   as	  
enumerated	   in	   the	   published	   literature.	   However,	   the	   UNC	   protocol	   deviates	   by	   employing	  
more	   aggressive	   urine	   screening	   post-­‐transplant	   to	   attempt	   to	   identify	   patients	   with	   viral	  
replication	  early	  on	  in	  BK	  virus	  reactivation	  to	  prevent	  the	  spread	  of	  infection	  or	  potential	  graft	  
loss.	  Additionally,	  a	  lower	  threshold	  for	  BK	  blood	  PCR	  levels	  is	  used	  when	  making	  the	  decision	  
to	  decrease	  a	  patient’s	  immunosuppression	  regimen.	  This	  protocol	  has	  proven	  to	  be	  effective	  in	  
minimizing	   graft	   loss	   in	   renal	   transplant	   patients	   secondary	   to	   BKVAN,	   with	   a	   3%	   graft	   loss	  
during	  the	  study	  period	  and	  patient	  follow-­‐up	  through	  August	  2014.	  
	   In	  addition	  to	  looking	  at	  graft	  loss	  rates,	  this	  study	  collected	  data	  to	  analyze	  the	  average	  
doses	  of	  the	  immunosuppressive	  regimens	  employed	  in	  patients	  post-­‐renal	  transplant,	  as	  seen	  
in	  Tables	  5	  and	  6.	  A	  lower	  average	  dose	  of	  mycophenolic	  acid	  and	  tacrolimus	  were	  seen	  in	  the	  
BKVAN	  group	  12-­‐months	  post-­‐transplant.	  This	  agrees	  with	  the	  dosage	  differences	  expected	  to	  
be	   seen	   upon	   following	   the	   BKVAN	   protocol	   used	   at	   UNC	   Hospitals,	   which	   first	   decreases	  
mycophenolic	  acid	  and	  tacrolimus	  doses	  as	  initial	  therapy.	  
The	   addition	   of	   steroids	   upon	   after	   biopsy-­‐confirmed	   BKVAN	   diagnosis	   is	   not	   a	  
universally	   used	  practice,	   however	   it	   has	   been	   implemented	   as	   protocol	   at	  UNC	  Hospitals	   as	  
adjunct	  therapy.	  Mean	  doses	  of	  prednisone	  after	  transplant	  were	  recorded,	  as	  seen	  in	  Table	  4	  
and	   found	   that	   there	   was	   a	   slight	   higher	   average	   dose	   in	   the	   BKVAN	   group	   1-­‐month	   post-­‐
transplant	   vs.	   no-­‐BKVAN.	   Further	   analysis	   of	   doses	   and	  prednisone	  use	  was	   investigated	   in	   a	  
further	  study	  assess	  overall	  use	  within	  this	  patient	  population.	  
	   As	  an	  addition	  to	  published	  treatment	  protocols,	  UNC	  Hospitals	  uses	  an	  antiproliferative	  
agent	   with	   the	   addition	   of	   leflunomide	   to	   replace	   mycophenolic	   acid	   derivatives,	   upon	  
diagnosis	  with	  BKVAN.	  Leflunomide	  is	  an	  antiviral	  that	  has	  an	  active	  metabolite,	  which	  inhibits	  
BKV	  replication,	  hypothesized	  to	  be	  through	  nonspecific	  pyrimidine	  depletion.	  The	  addition	   is	  
done	  in	  combination	  with	  total	  reduction	  of	  immunosuppression	  continuing	  the	  CNI	  and	  adding	  
corticosteroid	  therapy.	  There	  is	  a	  lack	  of	  prospective	  randomized	  trials	  to	  confirm	  the	  efficacy	  
of	   additive	   antivirals	   within	   this	   patient	   population14.	   However,	   UNC	   protocol	   dictates	   the	  
addition	  upon	  confirmatory	  diagnosis	  of	  BKVAN	  and	  has	  only	  seen	  1	  graft	   loss	  over	  the	  study	  
period	  further	  supporting	  this	  therapeutic	  addition.	  
	   Urine	   cytology	   is	   a	   non-­‐invasive,	   less	   expensive	   means	   of	   assessing	   for	   BK	   virus	  
replication.	   Performing	   these	   screens	   more	   frequently	   will	   allow	   providers	   to	   catch	   earlier	  
stages	  of	  BK	  virus	  replication	  in	  the	  hopes	  of	  preventing	  the	  spread	  of	  infection.	  While	  blood	  BK	  
PCR	  tests	  are	  more	  costly,	  Smith,	  F,	  et	  al.	   found	  significant	  cost	  savings	  with	   the	  reduction	   in	  
immunosuppression	   in	   patients	   with	   significant	   viremia15.	   It	   is	   proposed	   that	   these	   savings	  
would	  be	  enough	  to	  cover	  the	  more	  costly	  BK	  blood	  PCR	  tests	  required	  for	  monitoring.	  	  
	  
Study	  Limitations	  
	   A	   limitation	  of	   this	   study	  was	   the	   required	  use	  of	  multiple	   EMRs	   in	   this	   retrospective	  
chart	  analysis.	  The	  date	  range	  of	  data	  collection	  was	  chosen,	  as	  there	  was	  more	  consistent	  use	  
of	  TransChart	  for	  transplant	  patients,	  however	  there	  was	  inconsistency	  in	  some	  of	  the	  data	  that	  
was	  reported,	  and	  in	  the	  case	  of	  donor	  information	  there	  was	  some	  information	  omitted	  from	  
the	  records	  entirely.	  Additionally,	  the	  switch	  to	  a	  new	  EMR	  during	  the	  data	  collection	  proved	  to	  
be	  difficult	  for	  gathering	  any	  follow-­‐up	  data.	  
	   While	   average	   doses	   of	   tacrolimus	  were	   recorded	   for	   each	   patient	   at	   specified	   time-­‐
points	   post-­‐transplant,	   there	   was	   no	   data	   recorded	   on	   the	   measured	   serum	   levels	   of	  
tacrolimus.	   As	   the	   trough	   level	   of	   tacrolimus	   is	   the	  measure	   by	  which	   doses	   are	   changed,	   it	  
would	  be	  important	  to	  see	  if	  the	  doses	  were	  successful	  in	  getting	  patients	  to	  their	  optimal	  level	  
to	  improve	  graft	  survival.	  	  
The	  time	  at	  which	  the	  data	  was	  collected	  resulted	   in	  a	  variable	  about	  of	   follow-­‐up	  for	  
each	  patient,	  depending	  on	  his	  or	  her	  transplantation	  date.	  This	  time	  could	  have	  been	  too	  short	  
to	   see	   any	   true	   reactivation	   or	   progression	   to	   nephropathy	   in	   some	   patients,	   which	   would	  
warrant	  a	  longer	  follow-­‐up	  to	  see	  additional	  outcomes.	  
	   This	  was	  a	  small	  sample	  size	  obtained	  at	  a	  single	  institution.	  The	  purpose	  of	  this	  study	  
was	  to	  evaluate	  the	  protocol	  at	  a	  single	  institution	  and	  should	  be	  expanded	  in	  future	  studies	  to	  
include	  other	   institutions	  to	  determine	  the	  most	  successful	  protocol.	  Additionally,	  a	  follow-­‐up	  
time	  of	   5	   years	   is	   optimal	   in	   determining	   graft	   loss	  with	  BKVAN	  and	  was	  not	   necessarily	   the	  
amount	  of	  follow-­‐up	  for	  some	  patients	  included	  in	  this	  trial.	  
	  
Future	  Directions	  
	   The	   results	   of	   this	   study	   demonstrate	   the	   success	   of	   the	   post-­‐renal	   transplant	  
immunosuppression	  regimen	  used	  at	  UNC	  Hospitals	   in	  minimizing	  the	  potential	  graft	   loss	  due	  
to	  BK	  virus.	  However,	  some	  of	  the	  patients	  included	  in	  the	  date	  range	  of	  data	  collection	  had	  a	  
relatively	  short	  follow-­‐up	  period.	  Future	  directions	  for	  this	  research	  would	  include	  completing	  
the	  data	  collection	  for	  3-­‐year	  graft	  survival	  follow-­‐up	  as	  a	  better	  indicator	  of	  graft	  survival	  and	  
completing	   data	   collection	   for	   rejection	   episodes	   and	   treatment	   prior	   to	   BK	   virus	   diagnosis.	  
Additionally,	   having	   information	   regarding	   donor	   specific	   antibodies	   collected	   prior	   to	  
transplant	  would	  allow	  practitioners	  to	  be	  aware	  of	  patients	  that	  may	  be	  at	  a	  higher	  risk	  for	  BK	  
virus	  reactivation	  and	  may	  require	  alternative	  immunosuppression	  therapy	  goals.	  
	  
CONCLUSIONS	  
UNC	  Hospitals	  center	  specific	  results	  include	  a	  graft	  loss	  rate	  of	  3%	  among	  all	  diagnosed	  
stages	   of	   BKVN.	   In	   contrast	   to	   current	   guidelines,	   this	   center	   follows	   a	   protocol	   with	   more	  
aggressive	  post-­‐transplant	  urine	  cytology	  screening,	  a	  lower	  threshold	  for	  acquiring	  blood	  PCRs	  
and	   immunosuppression	   adjustment,	   along	  with	   the	   addition	   of	   leflunomide	   and	   prednisone	  
therapy	  and	  discontinuation	  of	  antiproliferatives	  with	  biopsy-­‐proven	  BKVAN.	  The	  results	  of	  this	  
study	  support	  the	  continued	  use	  of	  our	  current	  center	  BK	  protocol	  to	  minimize	  renal	  allograft	  
loss	  secondary	  to	  BKVAN.	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